Syndax Pharmaceuticals, Inc.

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

Kura Oncology and Kyowa Kirin plan to pursue US Food and Drug Administration approval based on positive Phase II topline results for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemi

Although last month Syndax Pharmaceuticals became the first company to win approval for a menin inhibitor from the US Food and Drug Administration, Johnson & Johnson is confident that it has a win

Syndax Pharmaceuticals will have a first-mover advantage as it launches Revuforj (revumenib) for relapsed/refractory acute leukemias in adult and pediatric patients with KMT2A translocations, followin